Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312699 · ClinicalTrials.gov registry record · Phase 1
Effects of Aging on Primary and Secondary Vaccine Responses
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03312699: Completed Phase 1 study, sponsored by Stanford University.
NCT03312699 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03312699, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the impaired vaccine responses in the elderly.
Interventions
- BIOLOGICAL Fluad
- BIOLOGICAL Fluzone High Dose
- BIOLOGICAL Fluzone® quadrivalent
- BIOLOGICAL Vaqta
- BIOLOGICAL Typhim Vi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03312699
The ClinicalTrials.gov registry entry for NCT03312699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluad is the first listed.
NCT03312699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03312699 about?
NCT03312699 is a clinical study titled "Effects of Aging on Primary and Secondary Vaccine Responses". The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (\>65 years) subjects whose yearly influenza vaccine responses have been studied extensively since 2007, to gain molecular and cellular mechanistic insights into the ...
What is the current status of trial NCT03312699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2017-09-19. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03312699?
The interventions under investigation include: Fluad (BIOLOGICAL), Fluzone High Dose (BIOLOGICAL), Fluzone® quadrivalent (BIOLOGICAL), Vaqta (BIOLOGICAL), Typhim Vi (BIOLOGICAL).
Who is sponsoring clinical trial NCT03312699?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.